Published in J Exp Med on November 05, 2001
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A (2009) 3.47
Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol (2013) 2.56
NF-kappaB and virus infection: who controls whom. EMBO J (2003) 2.08
Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology (2007) 1.77
The ubiquitin system, disease, and drug discovery. BMC Biochem (2008) 1.73
Host-pathogen interactions: subversion and utilization of the NF-kappa B pathway during infection. Infect Immun (2002) 1.65
Modulation of NF-κB signalling by microbial pathogens. Nat Rev Microbiol (2011) 1.64
Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol (2004) 1.63
The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A (2006) 1.58
Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis (2010) 1.40
Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog (2006) 1.34
Vpr and Vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo. J Virol (2004) 1.12
The Listeria monocytogenes InlC protein interferes with innate immune responses by targeting the I{kappa}B kinase subunit IKK{alpha}. Proc Natl Acad Sci U S A (2010) 1.11
Expression of NF-kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions. World J Gastroenterol (2004) 1.09
Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J Virol (2006) 1.08
HIV accessory proteins versus host restriction factors. Curr Opin Virol (2013) 1.08
Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J Virol (2007) 1.03
Genome-wide innate immune responses in HIV-1-infected macrophages are preserved despite attenuation of the NF-kappa B activation pathway. J Immunol (2009) 0.99
Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell Rep (2015) 0.98
Directed expression of the HIV-1 accessory protein Vpu in Drosophila fat-body cells inhibits Toll-dependent immune responses. EMBO Rep (2003) 0.93
HIV-1 Vpu - an ion channel in search of a job. Biochim Biophys Acta (2013) 0.91
Oligomerization of the human immunodeficiency virus type 1 (HIV-1) Vpu protein--a genetic, biochemical and biophysical analysis. Virol J (2007) 0.89
Dual transcriptomics of virus-host interactions: comparing two Pacific oyster families presenting contrasted susceptibility to ostreid herpesvirus 1. BMC Genomics (2014) 0.88
Torque teno virus (SANBAN isolate) ORF2 protein suppresses NF-kappaB pathways via interaction with IkappaB kinases. J Virol (2007) 0.87
The HIV-1 Vpu protein induces apoptosis in Drosophila via activation of JNK signaling. PLoS One (2012) 0.83
Genetic characterization of natural variants of Vpu from HIV-1 infected individuals from Northern India and their impact on virus release and cell death. PLoS One (2013) 0.82
Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets. Viruses (2014) 0.79
Immunotolerance of liver allotransplantation induced by intrathymic inoculation of donor soluble liver specific antigen. World J Gastroenterol (2003) 0.79
HIV-1 Vpu accessory protein induces caspase-mediated cleavage of IRF3 transcription factor. J Biol Chem (2014) 0.79
A Naturally Occurring rev1-vpu Fusion Gene Does Not Confer a Fitness Advantage to HIV-1. PLoS One (2015) 0.78
Recent Insights into HIV Accessory Proteins. Curr Infect Dis Rep (2003) 0.78
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors. ACS Med Chem Lett (2015) 0.78
Antibody against integrin lymphocyte function-associated antigen 1 inhibits HIV type 1 infection in primary cells through caspase-8-mediated apoptosis. AIDS Res Hum Retroviruses (2012) 0.78
BST-2/tetherin: viral tether, viral sensor or both? Future Virol (2013) 0.77
The emerging role of long non-coding RNAs in HIV infection. Virus Res (2015) 0.77
HIV-1 Vpr redirects host ubiquitination pathway. J Virol (2014) 0.77
Viral Membrane Channels: Role and Function in the Virus Life Cycle. Viruses (2015) 0.76
Efficient Vpu-mediated tetherin antagonism by an HIV-1 group O strain. J Virol (2017) 0.75
Primate Lentiviruses Modulate NF-κB Activity by Multiple Mechanisms to Fine-Tune Viral and Cellular Gene Expression. Front Microbiol (2017) 0.75
Pathway analysis for RNA-Seq data using a score-based approach. Biometrics (2015) 0.75
The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes. J Virol (2003) 0.75
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell (1997) 24.57
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol (2000) 20.70
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene (1999) 13.46
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 11.29
Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med (1995) 10.91
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994) 9.10
Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol (1999) 8.21
Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem (1999) 8.16
The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell (1995) 7.18
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell (1998) 5.89
Programmed death of T cells in HIV-1 infection. Science (1992) 5.63
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene (1999) 4.76
Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem (1999) 4.56
The simian immunodeficiency viruses. Annu Rev Immunol (1990) 4.32
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol (1999) 3.30
The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev (1999) 3.25
Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science (1994) 3.10
Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today (1994) 3.01
Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol (1999) 2.97
CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol (1990) 2.96
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82
Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev (1999) 2.82
Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol (1993) 2.63
The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med (2000) 2.62
Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol (1999) 2.52
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol (1995) 2.48
IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science (1998) 2.46
Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett (1996) 2.43
Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci U S A (1998) 2.42
Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol (1995) 2.22
Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. J Virol (1990) 2.21
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol (1996) 2.01
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J Virol (1998) 1.97
Mechanisms of HIV-associated lymphocyte apoptosis. Blood (2000) 1.75
Regulating protein degradation by ubiquitination. Immunol Today (1997) 1.71
The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem (2001) 1.69
Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol (2000) 1.61
Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases. Oncogene (1998) 1.51
Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1. J Virol (1991) 1.50
Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J Virol (1996) 1.46
Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol (1999) 1.37
Differences in the interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr (1990) 1.24
Cell surface CD4 inhibits HIV-1 particle release by interfering with Vpu activity. J Biol Chem (1999) 1.23
Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4. J Virol (1991) 1.20
Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol (1998) 1.18
Induction of "tissue" transglutaminase in HIV pathogenesis: evidence for high rate of apoptosis of CD4+ T lymphocytes and accessory cells in lymphoid tissues. Proc Natl Acad Sci U S A (1996) 1.03
Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS (1996) 0.99
Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res (1999) 0.99
Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis (2000) 0.98
Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing. J Virol (1999) 0.98
Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity. J Virol (1999) 0.96
Macrophage colony-stimulating factor antagonists inhibit replication of HIV-1 in human macrophages. J Immunol (2000) 0.93
Chemokines and chemokine receptors: role in HIV infection. Immunol Lett (1999) 0.89
Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques. Virology (1998) 0.88
NF-kappaB activation and HIV-1 induced apoptosis. Cytokine Growth Factor Rev (2000) 0.88
Does HIV cause depletion of CD4+ T cells in vivo by the induction of apoptosis? Immunol Cell Biol (1999) 0.85
Analysis of lymphocyte cell death and apoptosis in HIV-2-infected patients. Clin Exp Immunol (1994) 0.85
Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons. J Infect Dis (1997) 0.85
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell (1998) 5.89
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Nuclear access and action of notch in vivo. Cell (1998) 4.98
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins. J Virol (1986) 3.89
Nucleotide sequence and genome organization of foot-and-mouth disease virus. Nucleic Acids Res (1984) 3.81
Genetic recombination of human immunodeficiency virus. J Virol (1989) 3.61
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Mutational analysis of the human immunodeficiency virus vpr open reading frame. J Virol (1989) 3.48
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol (1991) 3.05
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol Cell (2000) 2.98
A second protease of foot-and-mouth disease virus. J Virol (1986) 2.87
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
Early replication block of human immunodeficiency virus type 1 in monkey cells. J Gen Virol (1995) 2.73
Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol (1993) 2.63
Structure of the FMDV translation initiation site and of the structural proteins. Nucleic Acids Res (1983) 2.58
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol (1995) 2.48
Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett (1996) 2.43
CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38
Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation. J Virol (1991) 2.30
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol (1993) 2.22
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIV (AGM). J Virol (1990) 1.99
The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif. J Mol Biol (1994) 1.93
Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc Natl Acad Sci U S A (1999) 1.87
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol (1990) 1.83
Molecular characterization of a polymerase mutant human immunodeficiency virus. Virology (1987) 1.76
Characterization of the env gene and long terminal repeat of molecularly cloned Friend mink cell focus-inducing virus DNA. J Virol (1984) 1.71
The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem (2001) 1.69
Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science (1993) 1.68
Characterization of bovine parainfluenza virus type 3. Microbiol Immunol (1979) 1.68
Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J Virol (1993) 1.63
Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. J Virol (1992) 1.59
Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett (1996) 1.56
Long terminal repeat of Friend-MCF virus contains the sequence responsible for erythroid leukemia. Virology (1985) 1.55
Sequences responsible for erythroid and lymphoid leukemia in the long terminal repeats of Friend-mink cell focus-forming and Moloney murine leukemia viruses. J Virol (1987) 1.55
Infectious foot-and-mouth disease virus derived from a cloned full-length cDNA. J Virol (1990) 1.54
Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J Gen Virol (1995) 1.52
Thiodiglycolic acid as a possible causative agent of fixed drug eruption provoked only after continuous administration of S-carboxymethyl-L-cysteine: case report and review of reported cases. Br J Dermatol (2005) 1.41
Cultured epidermal-sheet graft for epidermodysplasia verruciformis. Lancet (1998) 1.39
Concomitant abdominal aortic aneurysm repair and cholecystectomy. Combination of retroperitoneal aortic reconstruction and gassless laparoscopic cholecystectomy. J Cardiovasc Surg (Torino) (2000) 1.39
Acute follicular graft-versus-host disease. Dermatology (1992) 1.38
Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions. J Virol (2000) 1.38
SIV/HIV recombinants and their use in studying biological properties. AIDS Res Hum Retroviruses (1992) 1.35
Two concomitant base substitutions in the putative replicase genes of tobacco mosaic virus confer the ability to overcome the effects of a tomato resistance gene, Tm-1. EMBO J (1988) 1.35
A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization. Virus Genes (1989) 1.33
Rapid emergence of mink cell focus-forming (MCF) virus in various mice infected with NB-tropic friend virus. Virology (1981) 1.32
Human immunodeficiency virus Vpx is required for the early phase of replication in peripheral blood mononuclear cells. Microbiol Immunol (1994) 1.31
Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol (1999) 1.31
Functional comparison of transactivation by human retrovirus rev and rex genes. J Virol (1990) 1.27
Sequences present in the cytoplasmic domain of CD4 are necessary and sufficient to confer sensitivity to the human immunodeficiency virus type 1 Vpu protein. J Virol (1994) 1.27
Parainfluenza 3 virus: plaque-type variants lacking neuraminidase activity. Infect Immun (1981) 1.25
Cell surface CD4 inhibits HIV-1 particle release by interfering with Vpu activity. J Biol Chem (1999) 1.23
Growth ability of human immunodeficiency virus type 1 auxiliary gene mutants in primary blood macrophage cultures. J Gen Virol (1994) 1.22
Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther (2011) 1.18
Cloning and characterization of human MCM7 promoter. Gene (1998) 1.18
Antiapoptotic activity of herpes simplex virus type 2: the role of US3 protein kinase gene. Microbes Infect (1999) 1.17
The human immunodeficiency virus long terminal repeat is preferentially expressed in Langerhans cells in transgenic mice. AIDS Res Hum Retroviruses (1989) 1.17
Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. Curr Biol (1999) 1.17
Pseudotyping human immunodeficiency virus type 1 by vesicular stomatitis virus G protein does not reduce the cell-dependent requirement of vif for optimal infectivity: functional difference between Vif and Nef. J Gen Virol (1999) 1.14
Identification of bluetongue virus VP6 protein as a nucleic acid-binding protein and the localization of VP6 in virus-infected vertebrate cells. J Virol (1990) 1.11
High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer (1999) 1.10
HIV accessory proteins: multifunctional components of a complex system. Adv Pharmacol (2000) 1.10
Pancreatic pleural effusion: case report and review of 113 cases in Japan. Am J Gastroenterol (1992) 1.10
Construction and characterization of an infectious DNA clone and of mutants of simian immunodeficiency virus isolated from the African green monkey. J Virol (1990) 1.09
Influenza virus overcomes apoptosis by rapid multiplication. Int J Mol Med (1999) 1.08
Purification and characterization of the major group-specific core antigen VP7 of bluetongue virus synthesized by a recombinant baculovirus. J Gen Virol (1990) 1.08
Induction of apoptosis by herpes simplex virus type 1. J Gen Virol (1997) 1.08
Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology (1999) 1.08
Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr (1993) 1.06
Cell surface down-modulation of CD4 after infection by HIV-1. FASEB J (1994) 1.06
Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br J Radiol (2003) 1.03
Identification of a nucleotide deletion in parts of polypeptide 3A in two independent attenuated aphthovirus strains. Virology (1990) 1.02
The HIV-1 Vpr displays strong anti-apoptotic activity. FEBS Lett (1998) 1.02
Physiological significance of apoptosis in animal virus infection. Microbes Infect (2000) 1.01
Immunolocalization of hCDC47 protein in normal and neoplastic human tissues and its relation to growth. Int J Cancer (1997) 1.01
Complementation of the rev gene mutation among human and simian lentiviruses. J Virol (1990) 1.01
Human immunodeficiency virus type 1 vif, vpr, and vpu mutants can produce persistently infected cells. Arch Virol (1991) 1.01
Large-scale cDNA analysis of the maternal genetic information in the egg of Halocynthia roretzi for a gene expression catalog of ascidian development. Development (2001) 1.00
Diminution of CD4 surface protein but not CD4 messenger RNA levels in monocytic cells infected by HIV-1. AIDS (1991) 1.00
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch Virol (2001) 1.00